All methods were performed in accordance with the relevant guidelines and regulations
These findings provide insight into the potential benefits of GLP-1 RAs, but they are preliminary and warrant further investigation
In the GLP-1 vs DPP-4 inhibitor cohort (2009-2022), we identified 108,322 new users of GLP-1 RAs and 55,411 new users of DPP-4 inhibitors using the National Prescription Registry
In the adjusted cause-specific-hazard regression for the GLP-1 RA vs DPP-4 inhibitor cohort, GLP-1 RAs were associated with a lower risk of suicide or suicide attempts compared with DPP-4 inhibitors after 1 year follow-up (HR 365 0.58 [0.37;0.91])
If a provider prescribes it off-label for weight loss, coverage depends on your states obesity drug policies and is unlikely in most states
That experimental therapy combines GLP-1 and GIP with activation of nuclear hormone receptors known as PPARs targets once used by diabetes drugs like rosiglitazone and pioglitazone